Physician profile
Robert L Stein
NPI 1427091685
$2,778.78
in general payments reported to CMS, 2019-2025
23 companies · $336 in 2025
The $336 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $579 · 2021: $511 · 2022: $280 · 2023: $231 · 2024: $480 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $837.16 | 2019-2022 | |
| Alcon Vision LLC | $359.93 | 2021-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Sun Pharmaceutical Industries INC. | $286.67 | 2019-2023 | Cequa |
| Abbvie INC. | $227.54 | 2022-2024 | Lumigan, Vuity, Alphagan P |
| Biotissue Holdings INC. | $201.59 | 2020-2025 | |
| Tarsus Pharmaceuticals, INC. | $171.14 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $122.98 | 2019-2021 | |
| Dompe US, INC. | $80.61 | 2019-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $79.73 | 2021 | |
| Bausch & Lomb Americas INC. | $47.36 | 2022-2024 | Vyzulta, Lotemax Sm, Prolensa |
| Mallinckrodt Hospital Products INC. | $44.87 | 2024 | Acthar |
| Shire North American Group INC | $43.88 | 2019 | |
| Thea Pharma INC. | $43.60 | 2024-2025 | Iyuzeh |
| Oyster Point Pharma, INC. | $40.18 | 2022 | |
| Mallinckrodt Enterprises LLC | $31.45 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $31.14 | 2024 | Idose |
| Amgen INC. | $28.08 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $25.90 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $19.95 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ocular Therapeutix, INC. | $14.53 | 2021 | |
| Medline Industries LP | $12.00 | 2021 | |
| New World Medical,INC. | $9.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.